Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and… (NCT04004351) | Clinical Trial Compass
CompletedNot Applicable
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
1,531 participantsStarted 2013-09-16
Plain-language summary
Two-stage, prospective, observational, real-world study of HDM-SLIT-naïve children (aged 5-11) and adolescents (aged 12-17) consulting allergists or other specialist physicians in France for an HDM-induced allergy. Physician- and/or patient-reported data on clinical symptoms, sensitization, patient profiles, symptom burdens, patient-physician dialogue, HDM SLIT regimens, and effectiveness were recorded on inclusion, and then again 6 to 12 months after the prescription of an HDM SLIT solution.
The study's primary objective was to describe treatment modalities in children (aged from 5 to 11) and adolescents (aged from 12 to 17) with suspected HDM-induced AR or allergic asthma consulting an allergist or another specialist physician in France.
Who can participate
Age range5 Years – 17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Child or adolescent aged from 5 to 17.
✓. Patient suffering from House Dust Mites (HDMs)-associated allergic rhinitis, conjunctivitis and/or asthma.
✓. Sensitization to HDMs as proven by a skin prick test or a serum specific IgE assay.
✓. Patient eligible for HDMs sublingual immunotherapy.
✓. Patient who never received HDMs sublingual allergen immunotherapy.
✓. Patient in-print and orally informed on data recorded about him/her in connection with the study objectives.
✓. Patient and parents (or guardians) agreeing to participate in the study.
Exclusion criteria
✕. Age under 5 or over 18.
✕. Patient who already received HDMs sublingual allergen immunotherapy.
✕. Patient showing contra-indications to immunotherapy: immune disorder, immunodeficiency, malignancy.